ArticlePloS one2011
Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Molecular Insights from Differential Proteomic Profiling of Premalignant Cervical Lesions and Cervical Cancer.Pathogens (Basel, Switzerland) · 2026Article
- Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Identification of hub genes involved in cisplatin resistance in head and neck cancer.Journal, genetic engineering & biotechnology · 2023Article
- RNA-binding proteins modulate drug sensitivity of cancer cells.Emerging topics in life sciences · 2021Article
- STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma.Neoplasia (New York, N.Y.) · 2021Article
- Mitochondrial protein interaction landscape of SS-31.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.International journal of nanomedicine · 2020Article
- Article
- Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells.American journal of translational research · 2020Article
- Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics.Molecules (Basel, Switzerland) · 2019Review
- Expression proteomics study to determine metallodrug targets and optimal drug combinations.Scientific reports · 2017Article
- Quantitative Proteomic Analysis of Four Developmental Stages ofFrontiers in microbiology · 2017Article
- A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity.Current genomics · 2016Article
- Integrative topological analysis of mass spectrometry data reveals molecular features with clinical relevance in esophageal squamous cell carcinoma.Scientific reports · 2016Article
- Molecular mechanisms of cisplatin resistance in cervical cancer.Drug design, development and therapy · 2016Review
- Host-Microbe Protein Interactions during Bacterial Infection.Chemistry & biology · 2015Article
- Quantitative interactome analysis reveals a chemoresistant edgotype.Nature communications · 2015Article
- Systems biology of cisplatin resistance: past, present and future.Cell death & disease · 2014Review
- The evidence of HeLa cell apoptosis induced with tetraethylammonium using proteomics and various analytical methods.The Journal of biological chemistry · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Cisplatin along with other platinum based drugs are some of the most widely used chemotherapeutic agents. However drug resistance is a major problem for the successful chemotherapeutic treatment of cancer. Current evidence suggests that drug resistance is a multifactorial problem due to changes in the expression levels and activity of a wide number of proteins. A majority of the studies to date have quantified mRNA levels between drug resistant and drug sensitive cell lines. Unfortunately mRNA levels do not always correlate with protein expression levels due to post-transcriptional changes in protein abundance. Therefore global quantitative proteomics screens are needed to identify the protein targets that are differentially expressed in drug resistant cell lines. Here we employ a quantitative proteomics technique using stable isotope labeling with amino acids in cell culture (SILAC) coupled with mass spectrometry to quantify changes in protein levels between cisplatin resistant (HeLa/CDDP) and sensitive HeLa cells in an unbiased fashion. A total of 856 proteins were identified and quantified, with 374 displaying significantly altered expression levels between the cell lines. Expression level data was then integrated with a network of protein-protein interactions, and biological pathways to obtain a systems level view of proteome changes which occur with cisplatin resistance. Several of these proteins have been previously implicated in resistance towards platinum-based and other drugs, while many represent new potential markers or therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.